Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.55 |
| ▸ | NPC1 | O15118 | 4/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | CASP3 | P42574 | 2/20 | 0.49 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.49 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.49 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | ITK | Q08881 | 2/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11549930 | 0.81 | RAB9A (0.54) | RAB9ANPC1KDM4EMAPTMEN1 | |
| SCHEMBL22573025 | 0.81 | RAB9A (0.50) | RAB9ANPC1KDM4EMAPTMEN1 | |
| SCHEMBL374022 | 0.79 | RAB9A (0.74) | RAB9ANPC1KDM4EMAPTMEN1 | |
| SCHEMBL29631691 | 0.79 | RAB9A (0.74) | RAB9ANPC1KDM4EMAPTMEN1 | |
| SCHEMBL11558539 | 0.77 | RAB9A (0.57) | RAB9ANPC1KDM4EMAPTMEN1 | |
| SCHEMBL4689765 | 0.74 | RAB9A (0.52) | RAB9ANPC1KDM4EMAPTMEN1 | |
| SCHEMBL3135756 | 0.73 | NPC1 (0.71) | RAB9ANPC1KDM4EMAPTMEN1 | |
| SCHEMBL7917255 | 0.73 | RAB9A (0.50) | RAB9ANPC1KDM4EMAPTMEN1 | |
| SCHEMBL690118 | 0.73 | CYP19A1 (0.53) | RAB9ANPC1KDM4EMAPTMEN1 | |
| SCHEMBL4031802 | 0.73 | RAB9A (0.50) | RAB9ANPC1KDM4EMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114361341-A | Laminated image pickup device and image pickup module | 索尼公司 | 2022-04-15 | — | — | CN | claimed |
| CN-107534050-B | Image sensor, laminated image pickup device, and image pickup module | 索尼公司 | 2021-12-14 | — | — | CN | claimed |
| CN-112670425-A | Organic light emitting device | 三星显示有限公司 | 2021-04-16 | — | — | CN | claimed |
| CN-111316459-A | Photoelectric conversion element and imaging device | 索尼公司 | 2020-06-19 | — | — | CN | claimed |
| US-10566548-B2 | Image sensor, stacked imaging device and imaging module | SONY CORPORATION (JP) | 2020-02-18 | — | — | US | claimed |
| EP-3300114-B1 | IMAGING ELEMENT, MULTILAYER IMAGING ELEMENT AND IMAGING DEVICE | SONY CORP (JP) | 2020-01-08 | — | — | EP | claimed |
| US-20180114926-A1 | IMAGE SENSOR, STACKED IMAGING DEVICE AND IMAGING MODULE | SONY CORPORATION (JP) | 2018-04-26 | — | — | US | claimed |
| EP-3300114-A1 | IMAGING ELEMENT, MULTILAYER IMAGING ELEMENT AND IMAGING DEVICE | Sony Corporation (JP) | 2018-03-28 | — | — | EP | claimed |
| EP-2144889-B1 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC SRL (IT) | 2012-08-29 | — | — | EP | claimed |
| US-20110118258-A1 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC SRL (IT) | 2011-05-19 | — | — | US | claimed |
| EP-2144889-A2 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC S.r.l. (IT) | 2010-01-20 | — | — | EP | claimed |
| WO-2008142720-A2 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC SRL (IT) | 2008-11-27 | — | — | WO | claimed |
| EP-0770079-B1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2003-02-12 | — | — | EP | claimed |
| US-20020107251-A1 | Heterobicyclic derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-08-08 | — | — | US | claimed |
| US-6426345-B1 | PHOSPHODIESTERASE INHIBITORS; ANTIINFLAMMATORY AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-07-30 | — | — | US | claimed |
| EP-0770079-A1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-05-02 | — | — | EP | claimed |
| WO-1996001825-A1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-01-25 | — | — | WO | claimed |
| US-20230201161-A1 | Combination comprising HDAC inhibitor, LAG-3 inhibitor and a PD-1 inhibitor or PD-L1 inhibitor for cancer treatment | 4SC AG (DE) | 2023-06-29 | — | — | US | disclosed |
| EP-0770079-A1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-05-02 | — | — | EP | disclosed |
| WO-1996001825-A1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118258-A1 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90B1 | RAB9A 243/4885NPC1 3064/4885KDM4E 2835/4885 |
| US-20020107251-A1 | Heterobicyclic derivatives | ARSA, ARRB1, SULT2A1 | RAB9A 1092/4885NPC1 875/4885KDM4E 2663/4885 |
| US-20230201161-A1 | Combination comprising HDAC inhibitor, LAG-3 inhibitor and a PD-1 inhibitor or PD-L1 inhibitor for cancer treatment | HDAC1, HDAC3, HDAC11 | RAB9A 1283/4885NPC1 3699/4885KDM4E 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.